职 称：研究员
所属科室：药物代谢研究室
导师类别：硕士生导师
联系方式：shengli@imm.ac.cn
13683394069
所属重点实验室：创新药物非临床药物代谢及PK/PD研究北京市重点实验室
主要从事先导物药代特性早期评价及新方法研究、新药临床前药代动力学研究、药物代谢酶和转运蛋白调控的分子机制和生物学效应研究等。担任中国药理学会药物代谢专业委员会委员，中国药学会药物分析专业委员会委员。参与完成的8个1.1类新药（抗慢性肾功能不全药硝克柳胺，抗凝血药SAR107375E，抗结核药吡法齐明和OTB-658，PD-L1抑制剂艾姆地芬，抗糖尿病药LM49，抗肿瘤药安喹利司，镇静催眠药YZG-331）批准临床研究。主持和参与多项科研项目，包括国家科技部重大新药创制专项、国家自然科学基金、协和青年科研基金、中央级公益性科研院所基本科研业务费专项基金、青年医学教育学者计划项目等。发表科研论文30余篇，参编论著3部。
1. Jiang J, Luo L, Zhang Z*, Liu X, Chen N, Li Y, Sheng L*. The Active Glucuronide Metabolite of the Brain Protectant IMM-H004 with Poor Blood-Brain Barrier Permeability Demonstrates a High Partition in the Rat Brain via Multiple Mechanisms. Pharmaceutics. 2024;16(3):330.
2. Zhang Y, Deng J, Tian H, Qi H, Xiong T, Lin S, Dong Y, Luo L, Wu D, Zhang K, Ji M, Du T, Sheng L*, Chen X*, Xu H*. Design, Synthesis, and Bioevaluation of Novel Reversibly Photoswitchable PI3K Inhibitors Based on Phenylazopyridine Derivatives toward Light-Controlled Cancer Treatment. J Med Chem. 2024;67(5):3504-3519.
3. Zhou J, Wang W, Liu D, Xu S, Wang X, Zhang X, Wang X, Li Y, Sheng L*, Wang X*, Xu B*. Discovery of 2-Ethoxy-5-isobutyramido-N-1-substituted Benzamide Derivatives as Selective Kv2.1 Inhibitors with In Vivo Neuroprotective Effects. J Med Chem. 2024;67(1):213-233.
4. Luo LJ, Liu X, Li Y, Li Y, Sheng L*. Characterization of the metabolic contributions of cytochrome P450 isoforms to bicyclol using the relative activity factor method. J Asian Nat Prod Res. 2024:1-12.
5. Li Z, Zhang X, Wu H, Ma Z, Liu X, Ma J, Zhang D, Sheng L*, Chen X*, Zhang S*. Hydrangea paniculata coumarins attenuate experimental membranous nephritis by bidirectional interactions with the gut microbiota. Commun Biol. 2023;6(1):1189.
6. Zhou J, Du T, Wang X, Yao H, Deng J, Li Y, Chen X, Sheng L*, Ji M, Xu B. Discovery of Quinazoline-2,4(1H,3H)-dione Derivatives Containing a Piperizinone Moiety as Potent PARP-1/2 Inhibitors─Design, Synthesis, In Vivo Antitumor Activity, and X-ray Crystal Structure Analysis. J Med Chem. 2023;66(20):14095-14115.
7. Luo L, Liu X, Jin X, Liu Y, Ma J, Zhang S, Zhang D, Chen X, Sheng L*, Li Y. Simultaneous determination of skimmin, apiosylskimmin, 7-hydroxycoumarin and 7-hydroxycoumarin glucuronide in rat plasma by liquid chromatography-Orbitrap mass spectrometry and its application to pharmacokinetics. Biomed Chromatogr. 2022;36(1):e5223.
8. Luo L, Chang Y, Sheng L*. Gut-liver axis in the progression of nonalcoholic fatty liver disease: From the microbial derivatives-centered perspective. Life Sci. 2023;321:121614.
9. Weida Wang#, Li Sheng#, Yuanyuan Chen, Zhaojun Li, Haijie Wu, Jie Ma, Dongming Zhang, Xiaoguang Chen*, Sen Zhang*.(2021) Total coumarin derivates from Hydrangea paniculata attenuate renal injuries in cationized-BSA induced membranous nephropathy by inhibiting complement activation and interleukin 10-mediated interstitial fibrosis. Phytomedicine doi.org/10.1016/j.phymed.2021.153886.
10. Zhao H#, Gao Y#, Li W#, Sheng L#, Cui K, Wang B, Fu L, Gao M, Lin Z, Zou X, Jackson M, Huang H*, Lu Y*, Zhang D*. (2022) Design, Synthesis, and Biological Evaluation of Pyrrole-2-carboxamide Derivatives as Mycobacterial Membrane Protein Large 3 Inhibitors for Treating Drug-Resistant Tuberculosis. J Med Chem. 2022 Aug 11;65(15):10534-10553.
11. Li S, Liao H, Luo L, Meng B, Zheng F, Sheng L, Zhao H, Huan Y, Lei L, Zhai J, Zhao K, Tian J, Wu T, Li G, Pang J, Huang H. Proline-derived quinoline formamide compounds as human urate transporter 1 inhibitors with potent uric acid-lowering activities. Eur J Med Chem. 2024;269:116327.
12. Kong L, Zhao Q, Jiang X, Hu J, Jiang Q, Sheng L, Peng X, Wang S, Chen Y, Wan Y, Hou S, Liu X, Ma C, Li Y, Quan L, Chen L, Cui B, Li P. Trimethylamine N-oxide impairs β-cell function and glucose tolerance. Nat Commun. 2024;15(1):2526.
13. Ding W, Yan L, Sheng L, Chen S, Li Y, Cheng S, Luo L, Huang H, Shao H, Zhang D. Identification of Piperazinyl-Difluoro-indene Derivatives Containing Pyridyl Groups as Potent FGFR Inhibitors against FGFR Mutant Tumor: Design, Synthesis, and Biological Evaluation. J Med Chem. 2024;67(4):2941-2962.
14. Zhang K, Huang R, Ji M, Lin S, Lai F, Wu D, Tian H, Bi J, Peng S, Hu J, Sheng L, Li Y, Chen X, Xu H. Rational design and optimization of novel 4-methyl quinazoline derivatives as PI3K/HDAC dual inhibitors with benzamide as zinc binding moiety for the treatment of acute myeloid leukemia. Eur J Med Chem. 2024;264:116015.
15. Xia L, Jiang L, Du T, Lin S, Xiong T, Peng S, Tian H, Zhang K, Wu D, Sheng L, Ji M, Chen X, Xu H. Design, synthesis, and biological evaluation of novel bivalent PI3K inhibitors for the potential treatment of cancer. Bioorg Chem. 2023;140:106814.
16. Lin S, Du T, Zhang J, Wu D, Tian H, Zhang K, Jiang L, Lu D, Sheng L, Li Y, Ji M, Chen X, Xu H. Optimization of Benzamide Derivatives as Potent and Orally Active Tubulin Inhibitors Targeting the Colchicine Binding Site. J Med Chem. 2022;65(24):16372-16391.
17. Du T, Zhang Z, Zhou J, Sheng L, Yao H, Ji M, Xu B, Chen X. A Novel PARP Inhibitor YHP-836 For the Treatment of BRCA-Deficiency Cancers. Front Pharmacol. 2022;13:865085.
1. 《肠道菌与药物代谢》，王琰主编，科学出版社，2022.
2. 《应用分子药理学》第2版，王晓良主编，中国协和医科大学出版社，2015.
3. 《药理学研究的新技术与新方法》，陈晓光主编，中国协和医科大学出版社，2014.
1. 一种香豆素衍生物代谢产物的制备及其在防治脑缺血和阿尔茨海默病中的应用. 授权号：108727447B
2. 一类邻位羰基氨基取代苯衍生物的制备方法和用途. 授权号：111763164B
3. 吡咯-2-甲酰胺类化合物及其制备方法和用途. 授权号：111148734B
4. 一类吡喃并咔唑生物碱衍生物及其治疗阿尔茨海默症的用途. 授权号：114685519B
5. 一种普赛莫德的晶型及其制备方法和用途. 授权号：115974803B
6. 一种治疗神经退行性疾病的注射用浓溶液及其制备方法. 授权号：114377008B
